Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGA2115 dosing-regimen exploration in Chinese adults and adolescents with osteogenesis imperfecta types I, III, IV
CTR20261316Phase 2Active
- Sponsor
- Angitia Biopharmaceuticals
- Start
- Aug 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of AGA2115 in Osteogenesis imperfecta type I, Osteogenesis imperfecta type III, osteogenesis imperfecta type 4 (OI-IV), sponsored by Angitia Biopharmaceuticals. Started Aug 2026; status: active.
02
Drugs
AGA2115
03
Conditions
Osteogenesis imperfecta type IOsteogenesis imperfecta type IIIosteogenesis imperfecta type 4 (OI-IV)
Beyond the preview
Go deeper on CTR20261316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261316.